OrbiMed Advisors CCCC Position
Active5-Fund ConvergenceOrbiMed Advisors trimmed their position in C4 Therapeutics Inc. (CCCC) in Q4 2025, holding $2.7M worth of shares across 1,404,902 shares.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
CCCC is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Cemsidomide in 1445 days (Mar 31, 2030), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 14.7% of float with 4.2 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About C4 Therapeutics Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Full company profile →Short Interest
14.7%
4.2 days to cover
OrbiMed Advisors CCCC Position History
Frequently Asked Questions
Does OrbiMed Advisors own CCCC?
Yes. As of Q4 2025, OrbiMed Advisors holds 1,404,902 shares of C4 Therapeutics Inc. (CCCC) valued at $2.7M. This data comes from their SEC 13F filing.
How many hedge funds own CCCC?
5 specialist biotech hedge funds currently hold CCCC, including Commodore Capital, RA Capital Management, Tang Capital Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CCCC?
OrbiMed Advisors's position in CCCC was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CCCC position increasing or decreasing?
OrbiMed Advisors trimmed their CCCC position in the most recent quarter, reducing by 3,830,244 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CCCCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →